NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 193 filers reported holding NEKTAR THERAPEUTICS in Q1 2023. The put-call ratio across all filers is 0.02 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $2 | -71.4% | 3 | 0.0% | 0.00% | – |
Q4 2022 | $7 | -99.6% | 3 | -97.1% | 0.00% | – |
Q3 2020 | $2,000 | -96.9% | 103 | -97.2% | 0.00% | -100.0% |
Q1 2020 | $65,000 | +38.3% | 3,652 | +70.8% | 0.00% | +100.0% |
Q4 2019 | $47,000 | +840.0% | 2,138 | +1325.3% | 0.00% | – |
Q3 2019 | $5,000 | 0.0% | 150 | 0.0% | 0.00% | – |
Q2 2019 | $5,000 | -58.3% | 150 | -57.1% | 0.00% | -100.0% |
Q1 2019 | $12,000 | +50.0% | 350 | +40.0% | 0.00% | 0.0% |
Q4 2018 | $8,000 | -85.2% | 250 | -72.0% | 0.00% | -75.0% |
Q3 2018 | $54,000 | +20.0% | 894 | 0.0% | 0.00% | +33.3% |
Q2 2018 | $45,000 | +800.0% | 894 | +1688.0% | 0.00% | – |
Q1 2018 | $5,000 | -16.7% | 50 | -50.0% | 0.00% | -100.0% |
Q4 2017 | $6,000 | -14.3% | 100 | -75.0% | 0.00% | 0.0% |
Q3 2016 | $7,000 | +16.7% | 400 | 0.0% | 0.00% | 0.0% |
Q2 2016 | $6,000 | +200.0% | 400 | +100.0% | 0.00% | 0.0% |
Q3 2015 | $2,000 | 0.0% | 200 | 0.0% | 0.00% | 0.0% |
Q2 2015 | $2,000 | 0.0% | 200 | 0.0% | 0.00% | 0.0% |
Q1 2015 | $2,000 | – | 200 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
TOBAM | 640,547 | $21,522,000 | 1.09% |
Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |